- Home
- ESLA vs MIRA Comparison
ESLA vs MIRA Comparison
Compare ESLA & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | MIRA |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 43.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ESLA | MIRA |
|---|---|---|
| Price | $0.96 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 37.8K | ★ 75.0K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.90 |
| 52 Week High | $3.15 | $2.45 |
Technical Indicators
Market Signals| Indicator | ESLA | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 47.65 |
| Support Level | $0.97 | $0.91 |
| Resistance Level | $1.28 | $1.01 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 52.38 | 50.00 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.